Clover, Chengda IPOs Add To $1.2bn Raised By Chinese Bioventures
Executive Summary
The listings of two vaccine manufacturers and fundraisings by seven other biopharma ventures generate around $1.2bn in new financing for Chinese companies focusing on a broad variety of therapeutic areas and indicating continued investor interest.
You may also be interested in...
Abogen and Neurophth Lead China mRNA, Gene And Cell Therapy Funding Rush
Total of $571m raised in China from 10 venture capital and private equity funding deals betting heavily on mRNA and targeted oncology, as well as gene and cell therapies.
China’s First Insulin Tender Hits Multinationals Hard
An average overall price reduction of 48% for insulin products in China is expected to generate annual savings of $1.4bn through 2023, but multinational pharma firms will be hit hard by the bidding process.
Chinese Biotechs Step Onto World Stage With Innovative Products, Competitive Prices
In a new landmark, Chinese firm BeiGene has posted greater quarterly sales of its cancer drug Brukinsa in the US than in China for the first time. Meanwhile, a growing number of innovative products developed in China are on the cusp of expansion into overseas markets.